Protein kinase targeted therapeutics

Details Protein kinase targeted therapeutics Protein kinase targeted therapeutics

2011-04-05

2011-04-05

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252030, C544S238000

Reexamination Certificate

active

07919485

ABSTRACT:
The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).

REFERENCES:
patent: 4355029 (1982-10-01), Ridolfo
patent: 4590194 (1986-05-01), Lesher et al.
patent: 4623376 (1986-11-01), Speltz et al.
patent: 7452887 (2008-11-01), Dickson
patent: 2005/0130954 (2005-06-01), Mitchell
patent: 2006/050389 (2006-11-01), None
Stella et al ‘Prodrugs: Challenges and Rewards, Part 1’ Biotechnology: Pharmaceutical Aspects, p. 24, 2007.
Kyriakis JM and Avruch J “Mammalian Mitogen-Activated Protein Kinase Signal Transduction Pathways Activated by Stress and Inflammation” Physiol Rev (2001) 81: 808-869.
Bonni A, et al., “Cell Survival Promoted by theRas-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms,” Science. Nov. 12, 1999;286(5443):1358-62.
Chadee DN, “Direct Activation of Mitogen-Activated Protein Kinase Kinase Kinase MEKK1 by the Ste20p Homologue GCK and the Adapter Protein TRAF2” Mol Cell Biol. Feb. 2002;22(3):737-49.
Chang L, et al., “Mammalian MAP kinase signalling cascades,” Nature Mar. 1, 2001;410(6824):37-40.
Chen YR, et al., “Mammalian c-Jun N-terminal kinase pathway and STE20-related kinases,” Gene ther mol biol, Dec. 1999vol 4, 83-98.
Hazzalin CA, et al., “MAPK-Regulated Transcription: A Continuously Variable Gene Switch?,” Nat Rev Mol Cell Biol. Jan. 2002;3(1):30-40.
Kato Y, et al., “BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C,” EMBO J. Dec 1, 1997;16(23):7054-66.
Kiefer F, et al., “HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway,” EMBO J. Dec. 16, 1996;15(24):7013-25.
Pearson G, et al., “ERK5 and ERK2 Cooperate to Regulate NF-kB and Cell Transformation,” J Biol Chem. Mar 16, 2001;276(11):7927-31.
Weston CR, et al., “MAP Kinase Signaling Specificity,” Science. Jun. 28, 2002;296(5577):2345-7.
Kaminska B “MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits,” (2005) Biochim Biophys Acta 1754: 253-262.
Kumar S, et al., “P38 MAP Kinases: Key Signalling Molecules As Therapeutic Targets for Inflammatory Diseases,” Nature Rev Drug Discovery 2: 717-726 (2003).
Saklatvala J “The p38 MAP kinase pathway as a therapeutic target in inflammatory disease,” (2004) Curr Opin Pharmacol 4: 372-377.
Engelberg D , “Stress-activated protein kinases—tumor suppressors or tumor initiators?” (2004) Sem Cancer Biol 14: 271-282.
Rennefahrt U, et al., “Stress kinase signaling in cancer: fact or fiction?,” (2005) Cancer Lett 217: 1-9.
Schieven GL “The Biology of p38 Kinase: A Central Role in Inflammation,” (2005) Curr Topics Med Chem 5: 921-928.
Jinlian L “p38 MAPK in regulating cellular responses to ultraviolet radiation,” (2007) J Biomed Sci 14: 303-312.
Platanias LC “Review in Translational Hematology: Map kinase signaling pathways and hematologic malignancies” (2003) Blood 101: 4667-4679.
Knippschild U, et al., “The role of the casein kinase 1 family: participation in multiple cellular processes in eukaryotes,” 2005, Cellular Signalling 17: 675-689.
Knippschild U et al., 2005 “The Role of Casein Kinase 1 (CK1) Family in Different Signaling Pathways Linked to Cancer Development,” ONKOLOGIE 28: 508-514.
Ricchi et al., “Nonsteroidal Anti-Inflammatory Drugs in Colorectal Cancer: From Prevention to Therapy.” British Journal of Cancer 2003, vol. 88; p. 806.
Tamayo et al., “Design and sythesis of potent pyridazine inhibitors of p38 MAP kinase'Bioorganic and Medicinal Chemistry Letter,” (2005) vol. 15, P. 2409-2413.
International Search Report and Written Opinion from related International Patent Application No. PCT/US07/17375, Jul. 18, 2008.

Affiliated with

Also associated with

Rating

Protein kinase targeted therapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein kinase targeted therapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase targeted therapeutics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2646118